Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Technology and empathy help make remote working a success for Elsevier

Posted on July 29th, 2021 by in Pharma R&D

We at Elsevier were pleased to be one of five companies recognized for their ability to keep remote workers rooted in company culture in this recent Comparably article. Like many organizations during the pandemic, we had to quickly adapt to remote working on a large scale for our international workforce. As the article notes, “Elsevier took an empathetic and pragmatic approach in supporting its people and its customers and rapidly harnessed technology to work from home.”

(more…)

An Update on Global Availability of COVID-19 Vaccines from Editor of The Lancet

Posted on June 11th, 2021 by in Pharma R&D

In the U.S., the COVID-19 vaccine roll-out has moved at a strong pace, with about half of Americans now having received at least one shot. While many of the most motivated people have been able to get vaccinated by now, plenty of others still have questions. They may wonder if the vaccines are safe in general, or safe for them personally if they have a particular condition. They may have been confronted with conflicting information about the efficacy of vaccines.

(more…)

COVID-19 Treatment Trial Reaches Out to Communities of Color

Posted on April 5th, 2021 by in COVID-19

An ongoing problem in clinical trials over the years has been a failure to procure diverse enough representation among the participants. For a long time, this was due to bias and oversight on the part of the research community, and the consequence was a lack of full understanding in how medications and treatments affected women and various racial/ethnic minorities.

(more…)

Harris Poll Finds Large Boost in Pharma Industry Reputation

Posted on March 15th, 2021 by in Pharma R&D

As the COVID-19 vaccine roll-out gains in intensity, it has become common to hear people toss out the names of pharmaceutical companies like Pfizer, Moderna and AstraZeneca with the same ease that they refer to their favorite brands of ketchup or peanut butter. This isn’t typical. While direct-to-consumer advertising has perhaps increased some awareness of drug makers, the pandemic has made pharma R&D a subject of public interest in an unprecedented fashion.

(more…)

  1. 1
  2. 2
  3. 3
  4. 7